APA (7th ed.) Citation

N, A., EH, M., & A, S. (2026). Ravulizumab for relapse prevention in AQP4-IgG-positive neuromyelitis optica spectrum disorder: A 2-year follow-up case report. Frontiers in medicine, 13, 1827687. https://doi.org/10.3389/fmed.2026.1827687

Chicago Style (17th ed.) Citation

N, Akkawi, Mohamed EH, and Shatila A. "Ravulizumab for Relapse Prevention in AQP4-IgG-positive Neuromyelitis Optica Spectrum Disorder: A 2-year Follow-up Case Report." Frontiers in Medicine 13 (2026): 1827687. https://doi.org/10.3389/fmed.2026.1827687.

MLA (9th ed.) Citation

N, Akkawi, et al. "Ravulizumab for Relapse Prevention in AQP4-IgG-positive Neuromyelitis Optica Spectrum Disorder: A 2-year Follow-up Case Report." Frontiers in Medicine, vol. 13, 2026, p. 1827687, https://doi.org/10.3389/fmed.2026.1827687.